Bevacizumab treatment of prostate cancer (Q38024852)

27 August 2017

Bevacizumab treatment of prostate cancer (English)

1 reference

27 August 2017

1 reference

1 reference

2

1 reference

27 August 2017

Alexander C Small

1

0 references

language of work or name

English

0 references

publication date

9 July 2012

1 reference

Expert Opinion on Biological Therapy

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

9

1 reference

27 August 2017

1241-1249

1 reference

Tumor angiogenesis: therapeutic implications

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Tumor angiogenesis: molecular pathways and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

The biology of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Angiogenesis and prostate cancer: important laboratory and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Tumor cell proliferation and survival in patients with prostate cancer followed expectantly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Targeting angiogenesis for the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Early diagnosis of acute myeloid leukemia by computed tomography scan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Management of bevacizumab-associated bowel perforation: a case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Angiogenesis inhibition in prostate cancer: current uses and future promises.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

MET and VEGF: synergistic targets in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2012.704015

10.1517/14712598.2012.704015

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22775507